Page last updated: 2024-10-24

carvedilol and Familial Primary Pulmonary Hypertension

carvedilol has been researched along with Familial Primary Pulmonary Hypertension in 1 studies

Familial Primary Pulmonary Hypertension: Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Grinnan, D	1
Bogaard, HJ	1
Grizzard, J	1
Van Tassell, B	1
Abbate, A	1
DeWilde, C	1
Priday, A	1
Voelkel, NF	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension[NCT00964678]			Phase 1/Phase 2	10 participants (Actual)	Interventional	2010-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Absolute Change in Right Ventricular Ejection Fraction

Change in right ventricular ejection fraction is measured by cardiac magnetic resonance imaging, using the method of disks with the reading radiologist being blinded to before and after images. Cardiac magnetic resonance imaging was done at baseline and 6 months only (NCT00964678)
Timeframe: baseline, 6 months

Intervention	% RVEF (Mean)
Carvedilol	10.4

Change in 6 Minute Walk Distance

(NCT00964678)
Timeframe: baseline and 6 months

Intervention	feet (Number)
	Participant 1	Participant 2	Participant 3	Participant 5	Participant 6
Carvedilol	45	160	35	5	96

Change in Right Ventricular End Systolic Volume

right ventricular end systolic volume determined by MRI (NCT00964678)
Timeframe: baseline and 6 months

Intervention	mL (Number)
	Participant 1	Participant 2	Participant 3	Participant 4	Participant 5	Participant 6
Carvedilol	3	14	56	11	27	25

Change in Tricuspid Annular Plane Systolic Excursion

Higher values indicate a better outcome. (NCT00964678)
Timeframe: baseline and 6 months

Intervention	centimeters (Number)
	Participant 1	Participant 2	Participant 4	Participant 5	Participant 6
Carvedilol	0.4	-0.08	-0.12	0.45	0.08

Trials

1 trial available for carvedilol and Familial Primary Pulmonary Hypertension

Article	Year
Treatment of group I pulmonary arterial hypertension with carvedilol is safe. American journal of respiratory and critical care medicine, 2014, Jun-15, Volume: 189, Issue:12 Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Drug Administration Schedule; Familial Pr	2014